The Lattice (Official 3DHEALS Podcast)

3DHEALS
  • 5.0 (2)
  • Life Sciences
  • Updated Biweekly

Welcome to the Lattice podcast, the official podcast for 3DHEALS. This is where you will find fun but in-depth conversations (by founder Jenny Chen) with technological game-changers, creative minds, entrepreneurs, rule-breakers, and more. The conversations focus on using 3D technologies, like 3D printing and bioprinting, AR/VR, and in silico simulation, to reinvent healthcare and life sciences. This podcast will include AMA (Ask Me Anything) sessions, interviews, select past virtual event recordings, and other direct engagements with our Tribe.While there is no rule for our podcast content, the only rule we follow is to provide our listeners with a maximized return on their attention and time investment.Follow us on Facebook, Twitter, and Instagram @3dheals, and check out the links in the show notes. 3DHEALS Links: https://linktr.ee/3dheals 🛑 Disclaimer The content of this podcast is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The views and opinions expressed by the host and guests are their own and do not necessarily reflect those of their employers, affiliates, or any associated organizations. While we discuss emerging technologies in healthcare and 3D printing, listeners should consult qualified professionals before making decisions based on the information shared. The mention of specific companies, products, or technologies does not imply endorsement. This podcast may reference early-stage innovations and concepts that are not yet FDA-approved or commercially available. Always follow regulatory guidelines and ethical standards when applying new technologies in clinical or professional settings.

  1. Episode#117| Monica Wellejus:The Road to 3D-Printed Bone

    Jun 21

    Episode#117| Monica Wellejus:The Road to 3D-Printed Bone

    Ossiform is on track to bring the first 3D printed resorbable bone implant to the US market. The company’s preclinical data showed full bone regeneration in six months. Monica Wellejus, Chief Commercial Officer of Ossiform, joins The Lattice to explain how a company built to personalize bone implants for craniomaxillofacial surgeries is pivoting to mass-produced bone implants for foot deformity, and why hospital finance teams, not just the surgeons, may decide whether this technology actually reaches patients. ⚠️ Disclaimer: This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional 00:00 Intro | Why 3D printed bone has not reached patients yet 02:08 Meet Monica Wellejus and Ossiform 05:41 How Ossiform prints bone substitutes using β-TCP ceramics 10:12 The long road to FDA clearance and U.S. market entry 14:03 Why Ossiform moved away from personalized implants 18:26 Listening to surgeons changed everything 23:47 Flatfoot reconstruction and Ossiform’s first clinical products 30:18 Fundraising, commercialization, and building a MedTech startup 38: 54 The hidden decision-makers in healthcare adoption 46:31 The future of bone regeneration, AI, and point-of-care manufacturing Show notes: https://3dheals.com/episode-117-monica-wellejus-the-road-to-3d-printed-bone/ YouTube link:  https://youtu.be/E8t35WzV7Eg?si=QH-XHfJDwihvqv6n Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    44 min
  2. Episode #115| Professor Paul Dalton: Inventing Melt Electrowriting and the Future of Biofabricationrication

    Jun 4

    Episode #115| Professor Paul Dalton: Inventing Melt Electrowriting and the Future of Biofabricationrication

    What does it take to invent a technology that didn't exist before? In this episode, host Dr. Jenny Chen sits down with Professor Paul Dalton, the inventor of melt electrowriting (MEW) and one of the rare "triple threats" in science: an inventor, educator, and futurist. This is also a conversation about science, creativity, and why MEW isn't just a technology but a movement. Paul takes us from a boredom-filled childhood on a rural farm outside Perth, Australia, to the ophthalmic research lab where he helped build artificial corneas that restored sight to blind patients. He shares the moment a failing electrospinning experiment pushed him toward MEW instead — and the "breathless" discovery under the microscope that became MEW. Along the way, Jenny and Paul explore: What electrospinning and melt electrowriting actually are, explained in plain languageWhy MEW pulls fibers instead of pushing them, and how it prints at one-tenth of a teardrop per hourThe decades-long pursuit of clinical applicationsThe open-source "MEWron" printer is bringing MEW to labs for a fraction of the cost of commercial machinesThe two kinds of makers — builders vs. users — and where the community is headingPaul's advice for clinicians and newcomers entering biofabricationPlus, a remarkable offer for listeners at the end of this episode.  🔗 Show notes YouTube recording: Coming soon Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    59 min
  3. Episode#116| Event Recording: Advancing 3D Surgical Planning

    May 28

    Episode#116| Event Recording: Advancing 3D Surgical Planning

    Surgery is moving into a world where we can measure, simulate, and even rehearse before we ever touch a patient, but getting 3D surgical planning to feel “normal” inside a hospital is still a battle. We bring together a rare mix of voices across the ecosystem to explain what’s actually working, what’s still missing, and what it takes to scale medical 3D printing and virtual surgical planning without sacrificing safety or quality. Event Page: https://3dheals.com/3d-surgical-planning/ Subscribe, share this with someone building a 3D program, and leave a review with the biggest blocker you see to making 3D planning routine. Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    1h 59m
  4. Episode #114| Interview With Brigitte de Vet-Veithen, CEO of Materialise

    May 11

    Episode #114| Interview With Brigitte de Vet-Veithen, CEO of Materialise

    This is our second episode recorded at the Materialise conference.  Our guest for this episode is no other than the CEO of Materialise Brigitte de Vet-Veithen. It is a pleasure for me to be able to conduct this interview, because Materialise is such a legendary company that has spent 35 years building the software and services infrastructure behind patient-specific implants, surgical planning, and point-of-care manufacturing. We also got to know Brigitte as a person and the new leader of the company. Importantly, we covered the metrics that signal adoption, challenges to scale beyond the halo case, and her vision for the industry.  In my opinion, this is perhaps one of the most important conversations for the medical 3D printing industry in 2026. Highlights of this episode: • Brigitte's journey from MedTech leadership to being the CEO at Materialise • Why reimbursement is the clearest signal of adoption for medical 3D printing • Building health economics evidence for patient-specific devices when every case is unique • Helping physicians shift mindset toward pre-operative planning and new workflows • The move from “3D printing company” to solution partner for specific clinical needs • Why robots and surgical guides coexist, especially in ambulatory surgery centers • How AI compresses lead times and expands access for trauma patients • Mass personalization roadmap across orthopedics, CMF, pediatrics, respiratory, and structural heart • Global adoption differences and why imaging availability sets the pace • Investment priorities across education, evidence generation, R&D, and M&A Please listen to the disclaimer at the end of this podcast. Show Notes: https://3dheals.com/episode-114-interview-with-brigitte-de-vet-veithen-ceo-of-materialise/ YouTube: https://youtu.be/9PgME2RAmog?si=t-0X_DkrBdRg4MHe Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    42 min
  5. Episode#113| How 3D Printing Explains the Unexplainable in Congenital Heart Disease with Dr. Tristan Ramcharan

    May 10

    Episode#113| How 3D Printing Explains the Unexplainable in Congenital Heart Disease with Dr. Tristan Ramcharan

    This is one of two episodes we have recorded during our trip to Leuven Belgium for the Materialise 2026 Conference, focusing on 3D planning and 3D printing in hospitals. We talked with Dr. Tristan Remcharan about how pediatric cardiology imaging can become something you can literally hold, using 3D segmentation and 3D printing to make congenital heart disease easier to plan, teach, and explain. We also dig into the 2D versus 3D generational divide and the real-world funding hurdles that decide whether point-of-care 3D becomes routine care.  Show notes: https://3dheals.com/episode-113-how-3d-printing-explains-the-unexplainable-with-dr-tristan-ramcharan/ YouTube Video: https://youtu.be/eNUQWwJq5HM?si=3QhxXxvvUaEhO1MD The 3D cardiac printing program at Birmingham Children's Hospital is funded by charitable donations.  To support Tristan's works directly: Birmingham Children's Hospital Charity — https://www.bch.org.uk/appeal/donate Donate to the 3D cardiac printing program Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    16 min
  6. Episode# 112 | Automating Compounding Pharmacies: Prof. Alvaro Goyanes, FabRx

    Apr 23

    Episode# 112 | Automating Compounding Pharmacies: Prof. Alvaro Goyanes, FabRx

    You can learn a lot about the future of healthcare by watching how a single pill gets made. From a small office in London, we sit down with Prof Alvaro Goyanes, co-founder and CEO of FabRx, to unpack how 3D printed pharmaceuticals are turning personalized medicine from an idea into a working system. If you’ve ever wondered why patients still get forced into a handful of standard doses, this conversation shows what changes when medicine becomes software-driven and printable on demand.  We talk about what FabRx is building, why they’ve stayed deeply research-led while pushing toward clinical application, and how partnerships with hospitals are translating 3D printing into real studies. We also get specific about the compounding pharmacy workflow: “pharma ink” syringes prepared ahead of time, doses selected in software, and tablets printed with controls that reduce manual steps and help cut inconsistency. It’s a practical look at personalized drug manufacturing for therapies that need flexible dosing across pediatrics, elderly care, hormones, and more.  Quality is the backbone of everything here, so we dig into traceability, weighing each unit, pressure-sensing to catch extrusion problems early, camera systems that verify prints, and where AI inspection and near-infrared methods fit in. We zoom out to the policy layer, including the UK’s move toward distributed point-of-care manufacturing and how regulators in Europe and the US are beginning to shape guidance for 3D printing in pharmacies. Then we end on a wild but serious frontier: why NASA cares about printing medicines in space, where supply chains and gravity don’t cooperate.  If you care about personalized medicine, 3D printing in healthcare, and the future of compounding pharmacies, hit subscribe, share this with a friend in pharma or medtech, and leave a review telling us what application you want to see next. About Our Guest:  Alvaro Goyanes is the co-founder and CEO of FABRX, the first company dedicated to developing 3D printing technology for the fabrication of personalized medicines and medical devices. He is also an Honorary Associate Professor at University College London- School of Pharmacy (UK) and an Associate Professor at the Faculty of Pharmacy, University of Santiago de Compostela (Spain). A pioneer in the field, Alvaro was among the first researchers to explore the potential of 3D printing for manufacturing oral dosage forms and medical devices. Recognized as a world expert in 3D-printed medicines, he has been listed among the World's Most Highly Influential Researchers by Web of Science for six consecutive years since 2019. Alvaro holds a PhD in Pharmaceutics from the University of Santiago de Compostela and previously worked as a Registered Pharmacist for three years, giving him firsthand insight into the needs of community pharmacy. Show notes: Coming soon YouTube: Coming soon Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    16 min
  7. Episode #111| Bench to Bedside: Bioprinting Innovation Virtual Event Recording

    Apr 10

    Episode #111| Bench to Bedside: Bioprinting Innovation Virtual Event Recording

    Everyone talks about printing organs, but the closest thing to real impact often starts with something less flashy and far more practical: the materials. We bring together founders and operators working across bioprinted implants, structural bone substitutes, cryopreserved tissue models, and natural biopolymer manufacturing to answer one question that matters: what actually makes advanced biofabrication translate from bench to bedside? We dig into bone regeneration and why scaffolds fail when they can’t balance strength, vascular support, and predictable resorption. You’ll hear how absorbable polyurethane platforms aim to avoid acidic degradation while letting teams program mechanics and timelines, plus how 3D printed beta-tricalcium phosphate ceramics can deliver structural consistency and then remodel into native bone. The conversation stays grounded in the realities that decide adoption: predicates and evidence expectations for FDA 510(k), the heavier burden of EU MDR, and the uncomfortable truth that clearance doesn’t guarantee reimbursement. Then we shift to new approach methodologies for drug development, where cryobioprinting tackles the biggest blocker in bioprinted tissues: logistics. If tissues can be frozen, inventoried, shipped, and used on demand, bioprinting becomes a consumable workflow instead of an artisanal one-off. We close with a candid translation playbook for natural biopolymers and a high-volume pediatric use case: dissolvable chitosan ear tubes designed to reduce repeat surgeries, plus the pricing and coverage strategy needed to make that upgrade viable. Subscribe, share this with a builder in medtech or biotech, and leave a review with your biggest takeaway: which bottleneck matters most right now, materials, regulation, reimbursement, or scale-up? Event link: https://3dheals.com/bench-to-bedside-bioprinting-innovations/ YouTube highlights: Stay tuned Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    1h 49m
  8. Episode #110 | Neurotech Investing With Varun Turlapati, Chaanakya Capital

    Apr 10

    Episode #110 | Neurotech Investing With Varun Turlapati, Chaanakya Capital

    Neurotech is the category most investors whisper about and then walk away from: too technical, too regulated, too slow. We wanted to talk to someone who leans in anyway, so I sat down with Varun Turlapati, founder of Chanakya Capital, to hear how he’s building an early-stage fund dedicated to neurotech devices and why he thinks the “long horizon” objection often misses what’s actually happening on the ground. We unpack Varun’s path from software engineering into venture capital, including the mindset shift from analysis paralysis to fast iteration with smart guardrails. From there, we widen the frame on what neurotech means. Yes, brain-computer interfaces matter, but we also get into neuromodulation, bioelectronics, and the nervous system as the body’s command network, linking the brain, gut, and heart, and addressing disease. That lens turns “niche” into “everyone with a brain,” and it changes how you think about markets, clinical impact, and investable product strategy. Varun also shares the practical mechanics of deep tech investing: how he triages an 80+ company pipeline, separates “interesting” from “investable,” and brings in PhD scientists, physicians, and specialist advisors to evaluate clinical workflows and real differentiation. We dive into real examples across neuroprosthetics, Alzheimer’s, ADHD, and autism wearables, and a smart shunt for hydrocephalus, plus how regulatory signals like Breakthrough Device Designation can reshape the risk profile. If you care about neurotech startups, medical devices, FDA pathways, or where venture capital goes after AI becomes commoditized, this conversation will sharpen your evaluation of both science and execution. Subscribe to Lattice, share this with a founder or investor who’s curious about neurotech, and leave a review with the biggest question you still have about building in this space. Show notes: https://3dheals.com/episode-110-neurotech-investing-with-varun-turlapati-chaanakya-capital/ YouTube recording: coming soon Send us Fan Mail Support the show Subscribe to our premium version and support the show.  Follow us: Twitter  Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D

    1h 2m
See All (45)

Ratings & Reviews

5
out of 5
2 Ratings

About

Welcome to the Lattice podcast, the official podcast for 3DHEALS. This is where you will find fun but in-depth conversations (by founder Jenny Chen) with technological game-changers, creative minds, entrepreneurs, rule-breakers, and more. The conversations focus on using 3D technologies, like 3D printing and bioprinting, AR/VR, and in silico simulation, to reinvent healthcare and life sciences. This podcast will include AMA (Ask Me Anything) sessions, interviews, select past virtual event recordings, and other direct engagements with our Tribe.While there is no rule for our podcast content, the only rule we follow is to provide our listeners with a maximized return on their attention and time investment.Follow us on Facebook, Twitter, and Instagram @3dheals, and check out the links in the show notes. 3DHEALS Links: https://linktr.ee/3dheals 🛑 Disclaimer The content of this podcast is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The views and opinions expressed by the host and guests are their own and do not necessarily reflect those of their employers, affiliates, or any associated organizations. While we discuss emerging technologies in healthcare and 3D printing, listeners should consult qualified professionals before making decisions based on the information shared. The mention of specific companies, products, or technologies does not imply endorsement. This podcast may reference early-stage innovations and concepts that are not yet FDA-approved or commercially available. Always follow regulatory guidelines and ethical standards when applying new technologies in clinical or professional settings.

Information